Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3402-3408

  Tempero, Margaret ^a   Plunkett, William ^a   Van Haperen, Veronique Ruiz ^a   Hainsworth, John ^a   Hochster, Howard ^a   Lenzi, Renato ^a   Abbruzzese, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; GEMCITABINE TRIPHOSPHATE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT FAILURE; ADENOCARCINOMA; ADULT; AGED; COMPARATIVE STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0142121290     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.140     Document Type: Article

References (23)

1. Noble S, Goa KL: Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447-472, 1997
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
3. Heinemann V, Xu Y-Z, Chubb S, et al: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeoxcytidine. Mol Pharmacol 38:567-572, 1990
4. Huang P, Chubb S, Hertel LW, et al: Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
5. Huang P, and Plunkett W: Fludarabine and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188, 1995
6. Heinemann V, Xu Y-Z, Chubb S, et al: Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 52:533-539, 1992
7. Xu Y-Z, Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells: Action of 2′, 2′-difluorodeoxycytidipe. Biochem Pharmacol 44:1819-1827, 1992
8. Plunkett W, Huang P, Xu Y-Z, et al: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-9, 1995 (suppl 11)
9. Grunewald R, Kantarjian H, Keating MJ, et al: Pharmacologically directed design of the dose rate and schedule of 2′, 2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
10. Hughes TL, Hahn TM, Reynolds KK, et al: Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry 36:7540-7547, 1997
11. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
12. Von Hoff DD: Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with Gemcitabine: San Antonio Drug Development Team. Invest New Drugs 14:265-270, 1996
13. Csoka K, Liliemark J, Larsson R, et al: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22:47-53, 1995 (4 suppl 11)
14. Fossella FV, Lippman SM, Shin DM, et al: Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15:310-316, 1997
15. Brand R, Capadano M, Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331-341, 1997
16. Touroutoglou N, Gravel D, Raber MN, et al: Clinical results of a pharmacokinetically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003-1008, 1998
17. World Health Organization. The WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, WHO offset publication 48, 1979
18. Gibbons JD, Olkin I, Sobel M: Selecting and Ordering Populations: A New Statistical Methodology. New York, NY, Wiley, 1977
19. Mukhopadhyay N, Solanky TKS: Selection and Ranking Procedures: Second-Order Asymptomatics (Statistics: Textbooks and Mongraphs series, vol 142). New York, NY, Marcel Dekker, 1994
20. Sobel M: Nonparametric procedures for selecting the best population with the largest alpha-quantiles. Ann Math Stat 38:1804-1816, 1967
21. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
22. Storniolo AM, Enas NH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268, 1999
23. Ulrich-Pur H, Kornek GV, Raderer M, et al: A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 88:2505-2511, 2000